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INTRODUCTION
Obesity has been recognized as a worldwide problem, especially
for developing insulin resistance and increasing the risk of
type 2 diabetes. The increased adipose tissue associated with
obesity secretes various kinds of cytokines, adipokines and
lipokines, and triggers systemic inflammatory response, result-
ing in the disturbance of metabolic homeostasis.
Gastric inhibitory polypeptide/glucose-dependent insulinotro-
pic polypeptide (GIP) is an incretin secreted from enteroen-
docrine K cells in response to meal ingestion1, and potentiates
insulin secretion through the GIP receptor (GIPR) expressed in
pancreatic b-cells2. Dietary lipid is a very strong stimulant of
GIP secretion. For example, the peak value of GIP increase in
response to a high-fat meal (450 kcal containing 33.3% of fat)
is threefold higher than that in the 75-g oral glucose tolerance
test in human subjects, suggesting that fat content in a mixed
meal strongly stimulates GIP secretion1. Chronic high-fat con-
sumption induces hypersecretion of GIP from K cells3, and
insulin secretion in response to GIP is enhanced in high-fat
diet (HFD)-fed obese mice compared with that in lean mice
fed a normal-fat diet4, indicating that GIPR signaling plays a
critical role in postprandial hyperinsulinemia associated with
chronic HFD feeding and the subsequent increase in lipopro-
tein lipase activity, which results in HFD-induced fat accumula-
tion (Figure 1). Actually, reduction in GIPR signaling using
systemic GIPR knockout (GIPR-/-) mice5, a GIP antagonist6
and GIP immunoneutralization ameliorates obesity under
HFD-fed conditions. In addition, we have reported that genetic
deletion of GIP alleviates obesity and lessens the degree of
insulin resistance in HFD-fed mice7. In contrast, given that
functional GIPR is expressed in rodent and human adipocytes,
it has been assumed that GIP also has direct effects on adipose
tissue and plays some roles in lipid metabolism under HFD-
fed conditions.
GIP SIGNALING IN ADIPOSE TISSUE
In vitro studies have shown that GIP directly induces fat accu-
mulation in adipose tissue by increasing lipoprotein lipase
expression through the cyclic adenosine monophosphate
response element-binding protein (CREB)-regulated
transcription coactivator 2-mediated pathway, and by increasing
lipoprotein lipase enzyme activity and plasma membrane glucose
transporter 4 expression through the protein kinase B (PKB)-
mediated pathway8. However, the physiological significance of
GIPR signaling in adipocytes, namely, whether GIPR expressed
in adipose tissue plays some roles in HFD-induced obesity and
insulin resistance in vivo, has remained unproven.
To address this problem, we generated adipose tissue-specific
GIPR knockout (GIPRadipo-/-) mice9. Under HFD-fed condi-
tions, GIPRadipo-/- mice had significantly lower bodyweight and
lean body mass compared with those in floxed GIPR (GIPRfl/fl)
mice, although the fat volume was not significantly different
between the two groups. Interestingly, insulin resistance, liver
weight and hepatic steatosis were reduced in HFD-fed
GIPRadipo-/- mice compared with those in GIPRfl/fl mice.
Microarray analysis of adipose tissues showed that expression
of interleukin-6 (IL-6), a pro-inflammatory cytokine that
induces insulin resistance and hepatic steatosis10, was signifi-
cantly decreased in adipose tissue of GIPRadipo-/- mice, and
plasma levels of IL-6 were also reduced in HFD-fed GIPRadipo-/-
mice compared with those in HFD-fed GIPRfl/fl mice.
Previous in vitro studies have shown that GIP increases
IL-6 expression levels in adipose tissue11. In astrocytes,
CREB activated by b-adrenergic receptor enhances IL-6
expression induced by tumor necrosis factor (TNF)-a
receptor signaling12. It has been reported that GIP acti-
vates CREB in adipose tissue13. In our study using differ-
entiated 3T3-L1 adipocytes, IL-6 expression was
significantly augmented by GIP in the presence of TNF-a,
suggesting that GIP enhances IL-6 messenger ribonucleic
acid (mRNA) expression induced by TNF-a in adipose
tissue, possibly through CREB activation.
Suppressor of cytokine signaling (SOCS) protein is induced
by the activation of cytokine receptors, including the IL-6
receptor, TNF-a receptor and Toll-like receptors, and attenuates
cytokine signal transduction14. Seven SOCS proteins have been
identified, and SOCS1 and SOCS3 were recently reported to
negatively regulate insulin signaling by competitively interfering
with insulin receptor substrate binding to the insulin receptor15,
by inhibiting insulin receptor autophosphorylation16 and by
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promoting proteasomal degradation of insulin receptor sub-
strate17. In particular, SOCS3 signaling is located downstream
of the IL-6 receptor14, and is associated with insulin resistance
and hepatic steatosis18. Our in vitro experiments showed that
GIP induced mRNA expression of IL-6 and SOCS3 in the pres-
ence of TNF-a in differentiated 3T3-L1 adipocytes. In addition,
expression levels of SOCS3 mRNA were decreased in adipose
and liver tissues of GIPRadipo-/- mice. These results suggest that
a decrease in SOCS3 expression by GIPR deficiency might
enhance insulin sensitivity and potentiate PKB phosphorylation
in adipose and liver tissues. However, SOCS3 mRNA expres-
sion in skeletal muscle was not different between the two
groups of mice, although PKB phosphorylation was increased
in the skeletal muscle of GIPRadipo-/- mice. Further study
is required to clarify the mechanism of the increase in
insulin-induced PKB phosphorylation in the skeletal muscle of
GIPR adipo-/- mice.
It has also been reported that SOCS3 binds to the gene pro-
moter of sterol regulatory element-binding protein-1c (SREBP-
1c), which has critical roles in fat synthesis in the liver, and
increases SREBP-1c mRNA expression18. Suppression of SOCS3
expression in db/db mice improves the hepatic steatosis through
downregulation of SREBP-1c19. In our study, SREBP-1c and
SOCS3 mRNA expression were decreased in the liver of HFD-
fed GIPR adipo-/- mice, indicating that deletion of GIPR signal-
ing in adipocytes results in the decrease in IL-6 production
from adipose tissue and subsequent fat synthesis in the liver
through the IL-6–SOCS3–SREBP-1c pathway.
Although GIPR function in human adipose tissue is still
unclear in vivo, in vitro study shows that GIP induces IL-6
mRNA expression and potentiates IL-6 secretion in the pres-
ence of TNF-a in human adipocytes11, which is consistent with
our data showing that IL-6 mRNA expression is decreased in
the adipocytes of HFD-fed GIPRadipo-/- mice.
Based on the phenotypes of GIPRadipo-/- mice, it can be con-
cluded that GIPR signaling in adipose tissue plays an important
role in HFD-induced insulin resistance and hepatic steatosis
in vivo, with no direct effect on fat accumulation, through IL-6
signaling (Figure 1).
FUTURE PERSPECTIVE
As shown above, there is sufficient evidence to confirm that
GIP is an obesity-promoting factor in HFD conditions and
that deletion of GIPR signaling causes resistance to diet-
induced obesity. Additionally, we have reported that partial
reduction of GIP alleviates obesity and lessens the degree of
insulin resistance under HFD conditions7. These findings
suggest that regulation of GIPR signaling, especially after fat
intake, is a promising therapeutic approach to obesity and
type 2 diabetes. GIP antagonism is one of the candidates for
GIP-based treatment for diabetes and obesity. However, the
results in mice are not necessarily recapitulated in humans.
For example, previously developed (Pro3) GIP as a potent
antagonist of GIPR in mice was shown to stimulate GIPR in
humans20. In addition, given that GIPR is also expressed in
various tissues, except for pancreatic b-cells and adipocytes,
including the gastrointestinal tract, heart, inner layers of the
adrenal cortex and several brain regions, further investigation
is required to establish the systemic biological action of GIP
before the implementation of GIPR antagonism as an anti-
obesity/diabetes therapy to minimize unexpected adverse
events.
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Figure 1 | Schematic representation illustrating potential mechanisms by which GIP hypersecretion in high-fat diet conditions induces
insulin resistance and hepatic steatosis. GIP, gastric inhibitory polypeptide/glucose-dependent insulinotropic polypeptide; GIPR, gastric
inhibitory polypeptide/glucose-dependent insulinotropic polypeptide receptor; IR, insulin receptor; IL-6, interleukin-6; LPL, lipoprotein
lipase.
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